Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X:
“Phase II trial: [⁶⁸Ga]Ga-FAPI-46 PET-CT shows 90% PPV with IHC confirmation for detecting FAP-expressing tumors.
Strong correlation between uptake and tissue FAP expression. Emerging tool beyond FDG, incl. RCC & prostate cancer.
Title: [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
Authors: Kim M Pabst, Manuel M Weber, Christina Laschinsky, Patrick Sandach, Timo Bartel, Alina T Küper, Lukas Kessler, Marija Trajkovic-Arsic, Markus Eckstein, Elena Gilman, Michael Nader, Francesco Barbato, Lars E Podleska, Boris A Hadaschik, Rainer Hamacher, David Kersting, Nicola von Ostau, Bastian von Tresckow, Hans-Peter Kaelberlah, Claudia Kes, Sherko Kuemmel, Anke Reinacher-Schick, Martin Schuler, Jens T Siveke, Viktor Grünwald, Ken Herrmann, Wolfgang P Fendler
Read The Full Article at The Lancet Oncology.
More posts featuring Katy Beckermann.